Prostate cancer, malignant (ICD10 C61)

Five-year relative survival by stage and age at diagnosis (2003-2007 diagnosis period)

	Five-year relative survival (with 95% confidence interval) by stage at diagnosis (2003-2007)
Age at diagnosis	Total	Stage I	Stage II	Stage III	Stage IV	Unknown

all 15-99	92.8%	98.8%	99.9%	96.8%	35.7%	90.2%
(unstandardized)	(91.5-94.0%)	(91.8-100%)	(98.4-100%)	(93.0-100%)	(31.1-40.4%)	(86.8-93.3%)

all 15-99	89.9%	97.3%	97.7%	92.0%	37.5%	89.2%
(age-standardized)#	(86.7-92.8%)

15-44	95.5%	100.0%	99.5%	98.6%	45.0%	98.4%
	(93.3-97.2%)	-	(98.1-100%)	(89.1-100%)	(30.4-58.7%)	(88.3-100%)

45-54	96.8%	99.1%	99.8%	97.9%	46.8%	92.9%
	(95.3-98.1%)	(90.3-100%)	(98.1-100%)	(93.5-100%)	(35.1-57.7%)	(88.4-96.2%)

55-64	93.1%	98.9%	98.8%	95.6%	32.8%	94.8%
	(91.2-94.9%)	(90.0-100%)	(96.5-100%)	(89.1-100%)	(25.6-40.3%)	(90.5-98.5%)

65-74	82.4%	90.6%	95.9%	87.4%	31.9%	81.5%
	(78.1-86.5%)	(65.3-100%)	(89.7-100%)	(62.1-100%)	(24.4-40.1%)	(74.0-88.7%)

75-99	57.9%	100.0%	84.8%	48.0%	23.0%	47.6%
	(45.2-71.7%)	-	(59.8-100%)	(6.7-100%)	(10.6-40.9%)	(30.8-67.5%)

Footnotes:

AJCC stage (5th edition) is used here.

Patients with unspecified nodal status (N category) or distant metastatic status (M category) have been assumed to be N0 and M0, respectively.

This may result in some underestimation of survival for Stage II-III cases (particularly in older age-groups), based on comparisons with smaller samples of "strictly staged" cases.

Cases with unspecified T category are left unstaged unless N & M categories are sufficient to allow staging.

# Age-standardized figures use the standard patient population proposed for this cancer by:

Corazziari I., Quinn M. & Capocaccia R. 2004. Standard cancer patient population for age standardising survival ratios. Eur J Cancer 40: 2307-2316.

(Population weights = age 15-44 x7000, 45-54 x12000, 55-64 x23000, 65-74 x29000, 75-99 x29000)

Exclusions (as in EUROCARE):

Patients aged <15 or >99 at diagnosis; death-certificate-only (DCO) and autopsy-only cases; second or subsequent malignancies in the same patient

(or the less serious of two or more synchronously-diagnosed malignancies); in situ carcinomas and tumours of uncertain behaviour.